Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 4, 2002, Pages 413-420

  Devito, Claudia ^a   Hinkula, Jorma ^a   Kaul, Rupert ^a   Kimani, Joshua ^a   Kiama, Peter ^a   Lopalco, Lucia ^a   Barass, Claudia ^a   Piconi, Stefania ^a   Trabattoni, Daria ^a   Bwayo, Job J ^a   Plummer, Francis ^a   Clerici, Mario ^a   Broliden, Kristina ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Exposed; HIV 1 cross clade; IgA; Neutralization; Uninfected

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY;

ARTICLE; CONTROLLED STUDY; FEMALE; GENITAL SYSTEM; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION RISK; KENYA; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSTITUTION; PROTEIN PURIFICATION; RISK ASSESSMENT; SALIVA LEVEL; SERODIAGNOSIS; TRANSCYTOSIS; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

EID: 0036682591     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200208010-00007     Document Type: Article

References (40)

1. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
2. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
3. Role of cellular immunity in protection against HIV infection
4. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
5. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
6. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
7. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
8. Protective immunity against HIV-infection: Has nature done the experiment for us?
9. Immune responses in HIV-exposed seronegatives: Have they repelled the virus?
10. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
11. HIV-1 specific mucosal IgA in a cohort of HIV-1 resistant Kenyan sex workers
12. Epidemiologic and biologic characterization of a cohort of HIV-1 highly exposed, persistently seronegative commercial sex workers in Northern Thailand
13. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from The Gambia
14. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize primary HIV-1 isolates
15. Mucosal and plasma IgA from HIV-1 exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells
16. HIV neutralizing IgA in exposed seronegative subjects recognizes an epitope within the gp41 coiled-coil pocket
17. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya
18. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: Phenotypic and genotypic characteristics. WHO Network for HIV isolation and characterization
19. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type I infection
20. A method of obtaining, processing, and analyzing human intestinal secretions for antibody content
21. Antigen detection is a reliable method for evaluating HIV/SIV neutralization assays
22. Anti-HIV cellular immunity: Recent advances towards vaccine design
23. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection
24. HIV-1 specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1 resistant prostitutes in Nairobi
25. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa
26. Subtypes of HIV-1 compared to disease stage among women in Nairobi, Kenya
27. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype
28. Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes
29. Salivary sIgA response in HIV-1 infection
30. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1 infected patients
31. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons
32. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1
33. Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients
34. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure
35. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses
36. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences
37. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women